These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 751526)

  • 21. [Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites].
    Traina M; Vizzini GB
    Minerva Med; 1986 Jan; 77(3-4):87-91. PubMed ID: 3511409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
    Sadée W; Dagcioglu M; Schröder R
    J Pharmacol Exp Ther; 1973 Jun; 185(3):686-95. PubMed ID: 4712657
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
    Emili M; Cuppone R; Ricci GL
    Arzneimittelforschung; 1988 Oct; 38(10):1492-5. PubMed ID: 3058132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Aldosterone antagonists in coronary insufficiency].
    Osswald H
    Med Klin; 1978 Jan; 73(3):84-8. PubMed ID: 622061
    [No Abstract]   [Full Text] [Related]  

  • 25. Spironolactone interference with digoxin radioimmunoassay in cirrhotic patients.
    DiPiro JT; Cote JR; DiPiro CR; Bustrack JA
    Am J Hosp Pharm; 1980 Nov; 37(11):1518-21. PubMed ID: 7211855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new enzyme-linked chemiluminescent immunosorbent digoxin assay is virtually free from interference of spironolactone, potassium canrenoate, and their common metabolite canrenone.
    Dasgupta A; Kang E; Datta P
    J Clin Lab Anal; 2006; 20(5):204-8. PubMed ID: 16960898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of spironolactone and its metabolite canrenone on serum digoxin assays.
    Foukaridis GN
    Ther Drug Monit; 1990 Jan; 12(1):82-4. PubMed ID: 2305425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of Aldatense on laboratory tests. Comparison with a reference population].
    Hitz J; Steinmetz J; Henny J; Siest G
    Ann Biol Clin (Paris); 1984; 42(4):289-93. PubMed ID: 6149712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase.
    Finotti P; Palatini P
    J Pharmacol Exp Ther; 1981 Jun; 217(3):784-90. PubMed ID: 6262496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cardiac and selective vascular effects of canrenoate-potassium (aldactone pro injectione) in cardiosurgical patients (author's transl)].
    Piepenbrock S; Hempelmann G; Volkholz E; Oelert H
    Prakt Anaesth; 1977 Oct; 12(5):400-12. PubMed ID: 917981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.
    Dasgupta A; Johnson MJ; Sengupta TK
    J Clin Lab Anal; 2012 May; 26(3):143-7. PubMed ID: 22628228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium excretion and sodium-free volume expansion in dogs: effect of inhibition of aldosterone activity by canrenoate.
    Bie P
    Acta Physiol Scand; 1976 Oct; 98(2):272-4. PubMed ID: 983738
    [No Abstract]   [Full Text] [Related]  

  • 35. Canrenoate reversal of inhibitory effects of digoxin on basal and furosemide-stimulated renin secretion.
    Finotti P; Antonello A
    Clin Pharmacol Ther; 1982 Jul; 32(1):1-6. PubMed ID: 6282524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of potassium-canrenoate in the 3H-noradrenaline uptake and metabolism of the rat heart.
    Préda I; Sebeszta M; Antalóczy Z
    Arzneimittelforschung; 1980; 30(3):436-8. PubMed ID: 7387752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antioestrogenic action of the aldosterone antagonist canrenoate K in the rat (adenohypophysis, ceruloplasmin).
    Schreiber V; Pribyl T
    Physiol Bohemoslov; 1977; 26(5):385-95. PubMed ID: 144921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors of importance for valid digitalis assays particularly for the determination of digoxin in plasma and urine.
    Molin L
    Acta Pharmacol Toxicol (Copenh); 1986; 59 Suppl 4():1-62. PubMed ID: 3739734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of furosemide, potassium canrenoate and D-L-propranolol on blood pressure in spontaneously hypertensive rat].
    Altman J; Gordan P; Grünfeld JP
    Pathol Biol (Paris); 1976 May; 24(5):337-41. PubMed ID: 781602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of diuretics in preventing ascites recurrence.
    Arrigoni A; Andriulli A; Gindro T; Verme G
    Br J Clin Pract; 1988 Mar; 42(3):116-20. PubMed ID: 3207572
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.